Serum Uric Acid and Lipid Levels While Taking Topiramate for Migraine

Koçer, Abdülkadir; Dikici, Süber; Atakay, Selcuk; Okuyucu, Efika

doi:10.1111/j.1526-4610.2007.01008.x

Cited by 12 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TPM reduces enzymes responsible for fatty acids synthesis and enhances those of fatty acid β-oxidation [57], as well as mitochondrial function [58], which accelerates the β-oxidation rate of fatty acids. Albeit scarce data are available regarding the effect of TPM on TC level, yet previous studies support our finding, where TC level was decreased in epileptic adults treated with TPM [59], and migraine patients receiving TPM [60] and alcoholic patients subjected to TPM [61]. However, the exact mechanism for this effect has not been clearly elucidated.…”

Section: Discussionsupporting

confidence: 61%

Topiramate-Induced Modulation of Hepatic Molecular Mechanisms: An Aspect for Its Anti-Insulin Resistant Effect

El‐Abhar

Schaalan

2012

PLoS ONE

View full text Add to dashboard Cite

Topiramate is an antiepileptic drug known to ameliorate insulin resistance besides reducing body weight. Albeit liver plays a fundamental role in regulation of overall insulin resistance, yet the effect of topiramate on this organ is controversial and is not fully investigated. The current work aimed to study the potential hepatic molecular mechanistic cassette of the anti-insulin resistance effect of topiramate. To this end, male Wistar rats were fed high fat/high fructose diet (HFFD) for 10 weeks to induce obese, insulin resistant, hyperglycemic animals, but with no overt diabetes. Two HFFD-groups received oral topiramate, 40 or 100 mg/kg, for two weeks. Topiramate, on the hepatic molecular level, has opposed the high fat/high fructose diet effect, where it significantly increased adiponectin receptors, GLUT2, and tyrosine kinase activity, while decreased insulin receptor isoforms. Besides, it improved the altered glucose homeostasis and lipid profile, lowered the ALT level, caused subtle, yet significant decrease in TNF-α, and boosted adiponectin in a dose dependent manner. Moreover, topiramate decreased liver weight/, visceral fat weight/, and epididymal fat weight/body weight ratios. The study proved that insulin-resistance has an effect on hepatic molecular level and that the topiramate-mediated insulin sensitivity is ensued partly by modulation of hepatic insulin receptor isoforms, activation of tyrosine kinase, induction of GLUT2 and elevation of adiponectin receptors, as well as their ligand, adiponectin, besides its known improving effect on glucose tolerance and lipid homeostasis.

show abstract

Section: Discussionsupporting

confidence: 61%

Topiramate-Induced Modulation of Hepatic Molecular Mechanisms: An Aspect for Its Anti-Insulin Resistant Effect

El‐Abhar

Schaalan

2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…This indication is off-label and requires further study; particularly because a high BMI at baseline is not predictive of which migraine patients will lose weight on topiramate (Alberici et al, 2009). Topiramate monotherapy in migraine has been associated with significant elevations of serum uric acid, increasing risk of nephrolithiasis, and non-significant serum triglyceride elevation (Koçer et al, 2008). …”

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome and Migraine

Sachdev¹,

Marmura²

2012

Front. Neur.

View full text Add to dashboard Cite

Migraine and metabolic syndrome are highly prevalent and costly conditions. The two conditions coexist, but it is unclear what relationship may exist between the two processes. Metabolic syndrome involves a number of findings, including insulin resistance, systemic hypertension, obesity, a proinflammatory state, and a prothrombotic state. Only one study addresses migraine in metabolic syndrome, finding significant differences in the presentation of metabolic syndrome in migraineurs. However, controversy exists regarding the contribution of each individual risk factor to migraine pathogenesis and prevalence. It is unclear what treatment implications, if any, exist as a result of the concomitant diagnosis of migraine and metabolic syndrome. The cornerstone of migraine and metabolic syndrome treatments is prevention, relying heavily on diet modification, sleep hygiene, medication use, and exercise.

show abstract

“…Lipid levels in TPM-treated neurological patients have been examined in few previous investigations, only one of which was in adults with epilepsy; that study included only female patients (Franzoni et al, 2007;Kocer et al, 2008;Genc et al, 2010). These studies found no change in TC after TPM treatment; one found a small decline in HDL-C only (Genc et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Conversion from enzyme-inducing antiepileptic drugs to topiramate: Effects on lipids and c-reactive protein

et al. 2012

View full text Add to dashboard Cite

Serum Uric Acid and Lipid Levels While Taking Topiramate for Migraine

Abstract: Our results suggest a need for monitoring serum UA levels in patients receiving TPM. We should perhaps prescribe a low-UA diet and advice to drink much more water in these patients.

Cited by 12 publications

References 24 publications

Topiramate-Induced Modulation of Hepatic Molecular Mechanisms: An Aspect for Its Anti-Insulin Resistant Effect

Topiramate-Induced Modulation of Hepatic Molecular Mechanisms: An Aspect for Its Anti-Insulin Resistant Effect

Metabolic Syndrome and Migraine

Conversion from enzyme-inducing antiepileptic drugs to topiramate: Effects on lipids and c-reactive protein

Contact Info

Product

Resources

About